Evidence map›Paper›PMID 34587718›Full record

ArticleHaematologica2022

Planned withdrawal of dexamethasone after pomalidomide low-dose dexamethasone induction for lenalidomide-refractory multiple myeloma (ALLG MM14).

Anna Kalff, Tiffany Khong, Malarmathy Ramachandran, P Joy Ho, Peter Mollee, James D'Rozario, Kerry Taylor, Jane Estell, Sam Norton, Roslyn Kemp and 5 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Haematologica, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 2 papers.

0numbers the graph read from it
0cells of the map it votes in
2citing papers in PubMed
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

2 citing papers in PubMed.

  1. Article
  2. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

15 authors.

Anna KalffMalignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, Victoria, Australia; Myeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital-Monash University, Melbourne, Victoria, Australia; Department of Clinical Haematology, Monash University, Clayton, Victoria.
Tiffany KhongMalignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, Victoria, Australia; Myeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital-Monash University, Melbourne, Victoria.
Malarmathy RamachandranMalignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, Victoria, Australia; Myeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital-Monash University, Melbourne, Victoria.
P Joy HoRoyal Prince Alfred Hospital, Sydney.
Peter MolleePrincess Alexandra Hospital and University of Queensland, Brisbane.
James D'RozarioThe Canberra Hospital, Canberra.
Kerry TaylorIcon Cancer Centre, Brisbane.
Jane EstellConcord Repatriation General Hospital, University of Sydney, Sydney.
Sam NortonNanix Ltd., Dunedin, New Zealand; Department of Microbiology and Immunology, University of Otago.
Roslyn KempDepartment of Microbiology and Immunology, University of Otago.
Andrew J MitchellMaterials Characterisation and Fabrication Platform, Department of Chemical Engineering, University of Melbourne.
John ReynoldsDepartment of Epidemiology and Preventive Medicine, Alfred Health - Monash University, Melbourne, Victoria.
Nola KennedyMalignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, Victoria.
Hang QuachFaculty of Medicine, University of Melbourne, St Vincent's Hospital Melbourne, Australia [on behalf of The Australasian Leukaemia and Lymphoma Group (ALLG)].
Andrew SpencerMalignant Haematology and Stem Cell Transplantation, Alfred Hospital, Melbourne, Victoria, Australia; Myeloma Research Group, Australian Centre for Blood Diseases, Alfred Hospital-Monash University, Melbourne, Victoria, Australia; Department of Clinical Haematology, Monash University, Clayton, Victoria. Andrew.spencer@monash.edu.

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

PubMed holds no abstract for this paper.

Indexed as

Multiple MyelomaAntineoplastic Combined Chemotherapy ProtocolsDexamethasoneHumansLenalidomideThalidomideDexamethasoneLenalidomidepomalidomideThalidomide

Identifiers

PMID34587718
PMCPMC8719089

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.